MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study

Overexpression of ABCG2 transporter in cancer cells has been linked to the development of multidrug resistance (MDR), an obstacle to cancer therapy. Our recent study uncovered that the MET inhibitor, tepotinib, is a potent reversal agent for ABCB1-mediated MDR. In the present study, we reported for...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhuo-Xun, Teng, Qiu-Xu, Yang, Yuqi, Acharekar, Nikita, Wang, Jing-Quan, He, Min, Yoganathan, Sabesan, Lin, Jun, Wang, Jian, Chen, Zhe-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136566/
https://www.ncbi.nlm.nih.gov/pubmed/35646541
http://dx.doi.org/10.1016/j.apsb.2021.12.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136566/
https://www.ncbi.nlm.nih.gov/pubmed/35646541
http://dx.doi.org/10.1016/j.apsb.2021.12.018

Ejemplares similares